Skip to main navigation Skip to search Skip to main content

Targeting the IL-2 inducible kinase in melanoma; A phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: Preclinical rationale, biology, and clinical activity (NCI9922)

  • Stergios J. Moschos
  • , Zeynep Eroglu
  • , Nikhil I. Khushalani
  • , Kari L. Kendra
  • , George Ansstas
  • , Gino K. In
  • , Peng Wang
  • , Glenn Liu
  • , Frances A. Collichio
  • , Paul B. Googe
  • , Craig C. Carson
  • , Karen McKinnon
  • , Hsing Hui Wang
  • , Nana Nikolaishvilli-Feinberg
  • , Anastasia Ivanova
  • , Christy C. Arrowood
  • , Nancy Garrett-Mead
  • , Kathleen C. Conway
  • , Sharon N. Edmiston
  • , David W. Ollila
    • Jonathan S. Serody, Nancy E. Thomas, S. Percy Ivy, Lokesh Agrawal, Elizabeth C. Dees, James L. Abbruzzese

Research output: Contribution to journal › Article › peer-review

11   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Targeting the IL-2 inducible kinase in melanoma; A phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: Preclinical rationale, biology, and clinical activity (NCI9922)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science